PTC & Genzyme Restructure Ataluren Pact

PTC Therapeutics and Genzyme have announced the restructuring of their Ataluren collaboration.

Biopharmaceutical company PTC Therapeutics and Genzyme, a Sanofi company, have announced to restructure their Ataluren collaboration.

Under the original agreement, PTC held commercial rights for the U.S. and Canada and Genzyme held commercial rights in all other countries.

Under the revised agreement, PTC regains worldwide rights to ataluren and Genzyme retains an option to commercialize ataluren in indications other than nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) outside the U.S. and Canada. PTC will continue worldwide development in all indications with a focus on late-stage programs in nmDBMD and nonsense mutation cystic fibrosis.

David Me